147 related articles for article (PubMed ID: 16208003)
61. Selection of human immunodeficiency virus type 1 resistance against the pyranodipyrimidine V-165 points to a multimodal mechanism of action.
Hombrouck A; Hantson A; van Remoortel B; Michiels M; Vercammen J; Rhodes D; Tetz V; Engelborghs Y; Christ F; Debyser Z; Witvrouw M
J Antimicrob Chemother; 2007 Jun; 59(6):1084-95. PubMed ID: 17470918
[TBL] [Abstract][Full Text] [Related]
62. Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.
Singh K; Flores JA; Kirby KA; Neogi U; Sonnerborg A; Hachiya A; Das K; Arnold E; McArthur C; Parniak M; Sarafianos SG
Viruses; 2014 Sep; 6(9):3535-62. PubMed ID: 25254383
[TBL] [Abstract][Full Text] [Related]
63. Optimization of the oligonucleotide ligation assay for the detection of nevirapine resistance mutations in Zimbabwean Human Immunodeficiency Virus type-1 subtype C.
Mutsvangwa J; Beck IA; Gwanzura L; Manhanzva MT; Stranix-Chibanda L; Chipato T; Frenkel LM
J Virol Methods; 2014 Dec; 210():36-9. PubMed ID: 25239368
[TBL] [Abstract][Full Text] [Related]
64. Phenotypic resistance testing.
Andreoni M
Scand J Infect Dis Suppl; 2003; 106():35-6. PubMed ID: 15000580
[TBL] [Abstract][Full Text] [Related]
65. Simplified Paper Format for Detecting HIV Drug Resistance in Clinical Specimens by Oligonucleotide Ligation.
Panpradist N; Beck IA; Chung MH; Kiarie JN; Frenkel LM; Lutz BR
PLoS One; 2016; 11(1):e0145962. PubMed ID: 26751207
[TBL] [Abstract][Full Text] [Related]
66. Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1.
Qari SH; Respess R; Weinstock H; Beltrami EM; Hertogs K; Larder BA; Petropoulos CJ; Hellmann N; Heneine W
J Clin Microbiol; 2002 Jan; 40(1):31-5. PubMed ID: 11773089
[TBL] [Abstract][Full Text] [Related]
67. Use of genotypic assays for the detection of HIV antiretroviral resistance.
Nicastri E; Ippolito G
Scand J Infect Dis Suppl; 2003; 106():24-8. PubMed ID: 15000578
[TBL] [Abstract][Full Text] [Related]
68. Candidate antiretroviral agents for use in postexposure prophylaxis.
Saag MS
Am J Med; 1997 May; 102(5B):25-31. PubMed ID: 9845493
[No Abstract] [Full Text] [Related]
69. An Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 Quasispecies.
Martín V; Perales C; Fernández-Algar M; Dos Santos HG; Garrido P; Pernas M; Parro V; Moreno M; García-Pérez J; Alcamí J; Torán JL; Abia D; Domingo E; Briones C
PLoS One; 2016; 11(12):e0166902. PubMed ID: 27959928
[TBL] [Abstract][Full Text] [Related]
70. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses.
Descamps D; Collin G; Letourneur F; Apetrei C; Damond F; Loussert-Ajaka I; Simon F; Saragosti S; Brun-Vézinet F
J Virol; 1997 Nov; 71(11):8893-8. PubMed ID: 9343254
[TBL] [Abstract][Full Text] [Related]
71. Performance of an in-house human immunodeficiency virus type 1 genotyping system for assessment of drug resistance in Cuba.
Alemán Y; Vinken L; Kourí V; Pérez L; Álvarez A; Abrahantes Y; Fonseca C; Pérez J; Correa C; Soto Y; Schrooten Y; Vandamme AM; Van Laethem K
PLoS One; 2015; 10(2):e0117176. PubMed ID: 25671421
[TBL] [Abstract][Full Text] [Related]
72. Characterization and use of a recombinant retroviral system for the analysis of drug resistant HIV.
Medina DJ; Tung PP; Nelson CJ; Sathya B; Casareale D; Strair RK
J Virol Methods; 1998 Apr; 71(2):169-76. PubMed ID: 9626950
[TBL] [Abstract][Full Text] [Related]
73. Simple detection of point mutations associated with HIV-1 drug resistance.
Frater AJ; Chaput CC; Beddows S; Weber JN; McClure MO
J Virol Methods; 2001 Apr; 93(1-2):145-56. PubMed ID: 11311353
[TBL] [Abstract][Full Text] [Related]
74. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay.
Boucher CA; Keulen W; van Bommel T; Nijhuis M; de Jong D; de Jong MD; Schipper P; Back NK
Antimicrob Agents Chemother; 1996 Oct; 40(10):2404-9. PubMed ID: 8891152
[TBL] [Abstract][Full Text] [Related]
75. Variety of interpretation systems for human immunodeficiency virus type 1 genotyping: confirmatory information or additional confusion?
Stürmer M; Doerr HW; Preiser W
Curr Drug Targets Infect Disord; 2003 Dec; 3(4):373-82. PubMed ID: 14754436
[TBL] [Abstract][Full Text] [Related]
76. Discovering why HIV drugs fail.
Check W
CAP Today; 1999 Oct; 13(10):1, 12-6, 20 passim. PubMed ID: 10623385
[No Abstract] [Full Text] [Related]
77. [Development of microchips for the detection of mutations of HIV-1 variability to protease inhibitors and the usage results].
Rudinskiĭ NI; Mikhaĭlovich VM; Donnikov MIu; Lapa SA; Sukhanova AL; Kazennova EV; Bobkov AF; Zasedatelev AS; Pokrovskiĭ VV; Mirzabekov AD
Vopr Virusol; 2004; 49(6):10-5. PubMed ID: 15597954
[TBL] [Abstract][Full Text] [Related]
78. Are subtype differences important in HIV drug resistance?
Lessells RJ; Katzenstein DK; de Oliveira T
Curr Opin Virol; 2012 Oct; 2(5):636-43. PubMed ID: 23006584
[TBL] [Abstract][Full Text] [Related]
79. Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections.
Rayner MM; Cordova B; Jackson DA
Virology; 1997 Sep; 236(1):85-94. PubMed ID: 9299620
[TBL] [Abstract][Full Text] [Related]
80. Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates.
Puertas MC; Buzón MJ; Ballestero M; Van Den Eede P; Clotet B; Prado JG; Martinez-Picado J
J Clin Microbiol; 2012 Dec; 50(12):3909-16. PubMed ID: 23015664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
